Trials Sponsors Conditions Drugs Pricing

Conditions

Obesity Diabetes Mellitus, Non-Insulin-Dependent Obesity in Diabetes

Keywords

DiabetesObesity

Outcome Measures

Primary Outcomes (1)

Change in body weight

Secondary Outcomes (1)

Metabolic parameters

Interventions

Rimonabant (SR141716)Drug

Eligibility Criteria

Age18 Years - 70 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

* BMI must be greater than 27 and less than 40 * Treated Type 2 Diabetes on single therapy treatment for at least 1 year * Stable weight (variation of less than 5 kg within 3 months prior to screening visit)

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Sanofi
Industrylead

Study Sites (55)

Innovative Clinical Trials

Birmingham, Alabama, 35209, United States

Lovelace Scientific Resources

Phoenix, Arizona, 85016, United States

Advanced Clinicla Therapeutics, LLC

Tucson, Arizona, 85712, United States

Southern California Prevention and Research Center Inc. (SPARC)

Encino, California, 91436, United States

Anderson Clinical Research

San Bernardino, California, 92408, United States

Diablo Clinical Research, Inc.

Walnut Creek, California, 94598, United States

North East Clinical Research

Related Publications (1)

Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006 Nov 11;368(9548):1660-72. doi: 10.1016/S0140-6736(06)69571-8.
PMID: 17098084RESULT

MeSH Terms

Conditions

ObesityDiabetes Mellitus, Type 2Diabetes Mellitus

Interventions

Rimonabant

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsGlucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases

Study Officials

ICD CSD
Sanofi
STUDY DIRECTOR

Enrollment

1,045 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, INVESTIGATOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

January 23, 2002

First Posted

January 24, 2002

Study Start

October 2001

Date type not reported

This date has not been verified as actual or estimated.

Obese Patients With Type 2 Diabetes

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (55)

Related Publications (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (55)

Related Publications (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations